Comments on: FTC Holds Roundtable On Follow-On Biologics http://www.pharmalot.com/2008/11/ftc-to-hold-roundtable-on-follow-on-biologics/ News, Comment and Conversation Fri, 10 Feb 2012 22:43:58 +0000 http://wordpress.org/?v=2.6.2 By: Stinky http://www.pharmalot.com/2008/11/ftc-to-hold-roundtable-on-follow-on-biologics/#comment-382695 Stinky Mon, 24 Nov 2008 01:29:29 +0000 http://www.pharmalot.com/?p=17807#comment-382695 Ed, Any scoop on what was discussed at the meeting? Ed,
Any scoop on what was discussed at the meeting?

]]> By: Stinky http://www.pharmalot.com/2008/11/ftc-to-hold-roundtable-on-follow-on-biologics/#comment-382694 Stinky Mon, 24 Nov 2008 01:28:53 +0000 http://www.pharmalot.com/?p=17807#comment-382694 This wouldn't lead to a destruction, the margins would still be largely intact, unlike small molecule pharma. Should biotechs get an infinite patent life, and be able to charge upwards of $100k/year for certain specialty products for eternity? I think not, there is more than enough money at lower margins for their business models to be comfortably sustainable. Stinky This wouldn’t lead to a destruction, the margins would still be largely intact, unlike small molecule pharma. Should biotechs get an infinite patent life, and be able to charge upwards of $100k/year for certain specialty products for eternity? I think not, there is more than enough money at lower margins for their business models to be comfortably sustainable.

Stinky

]]> By: parson http://www.pharmalot.com/2008/11/ftc-to-hold-roundtable-on-follow-on-biologics/#comment-382675 parson Sun, 23 Nov 2008 21:46:12 +0000 http://www.pharmalot.com/?p=17807#comment-382675 Excellent. The destruction of the specialty pharma and biotech sectors is almost complete. 我希望你讲中国. Excellent. The destruction of the specialty pharma and biotech sectors is almost complete.

我希望你讲中国.

]]> By: B Billings http://www.pharmalot.com/2008/11/ftc-to-hold-roundtable-on-follow-on-biologics/#comment-382560 B Billings Sat, 22 Nov 2008 17:22:55 +0000 http://www.pharmalot.com/?p=17807#comment-382560 It's mind boggling that generic versions of biologic medicines are approved and available to patients in 11 countries outside the U.S. but not here at home. Why? Because for some reason we failed to have the foresight to give FDA a regulatory process to approve these products. Meanwhile, with no competition from generics, prices for brand biologic drugs continue to skyrocket. Hopefully now, with support from the new President and the FTC, we can catch up with the rest of the world and begin providing safe, effective and less-expensive versions of these critical medicines. It’s mind boggling that generic versions of biologic medicines are approved and available to patients in 11 countries outside the U.S. but not here at home. Why? Because for some reason we failed to have the foresight to give FDA a regulatory process to approve these products. Meanwhile, with no competition from generics, prices for brand biologic drugs continue to skyrocket. Hopefully now, with support from the new President and the FTC, we can catch up with the rest of the world and begin providing safe, effective and less-expensive versions of these critical medicines.

]]>